Hilltop Holdings Inc. Grows Stake in Kenvue Inc. (NYSE:KVUE)

Hilltop Holdings Inc. grew its position in Kenvue Inc. (NYSE:KVUE) by 3.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 80,331 shares of the company’s stock after buying an additional 2,434 shares during the quarter. Hilltop Holdings Inc.’s holdings in Kenvue were worth $1,858,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Riverview Trust Co bought a new position in Kenvue during the 3rd quarter worth about $30,000. Ashton Thomas Securities LLC bought a new position in Kenvue in the third quarter worth approximately $35,000. Studio Investment Management LLC lifted its holdings in Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after buying an additional 845 shares during the period. Deseret Mutual Benefit Administrators increased its holdings in shares of Kenvue by 49.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after acquiring an additional 651 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Kenvue in the 2nd quarter worth $61,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

NYSE:KVUE opened at $23.49 on Wednesday. The firm’s fifty day moving average is $22.97 and its two-hundred day moving average is $21.04. The firm has a market cap of $45.04 billion, a price-to-earnings ratio of 42.71, a PEG ratio of 2.20 and a beta of 1.37. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue’s quarterly revenue was down .4% on a year-over-year basis. During the same period last year, the business earned $0.31 earnings per share. Research analysts expect that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.49%. Kenvue’s payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on KVUE. Jefferies Financial Group started coverage on Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price on the stock. Piper Sandler boosted their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. Bank of America lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. JPMorgan Chase & Co. increased their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.